Acute Leukemias - Republican Scientific Medical Library

More documents

Recommendations

Info

72 Chapter 4 · Relapsed and Refractory Acute Myeloid Leukemia older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 98(5):1302–1311 7. Lee S, Tallman MS, Oken MM, et al. (2000) Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Eastern Cooperative Oncology Group. Leukemia 14(8):1345–1348 8. Estey EH (2000) Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 14(3):476–479 9. Keating MJ, Kantarjian H, Smith TL, et al. (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7(8):1071–1080 10. Breems DA, Van Putten WL, Huijgens PC, et al. (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23(9):1969–1978 11. Giles F, Verstovsek S, Garcia-Manero G, et al. (2006) Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 134(1):58–60 12. Lo Coco F, Diverio D, Avvisati G, et al. (1999) Therapy of molecular relapse in acute promyelocytic leukemia. Blood 94(7):2225–2229 13. Marcucci G, Mrozek K, Ruppert AS, et al. (2004) Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: Results from cancer and leukemia group B study 8461. J Clin Oncol 22(12):2410–2418 14. Sternberg DW, Aird W, Neuberg D, et al. (2000) Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: A pharmacologically based regimen. Cancer 88(9):2037–2041 15. Kern W, Aul C, Maschmeyer G, et al. (1998) Superiority of highdose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison. Leukemia 12(7):1049–1055 16. Rees JK, Gray RG, Swirsky D, et al. (1986) Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial. Lancet 2(8518):1236–1241 17. Appelbaum FR, Rowe JM, Radich J, et al. (2001) Acute myeloid leukemia hematology. Am Soc Hematol Educ Program, pp 62–86 18. Burnett AK, Mohite U (2006) Treatment of older patients with acute myeloid leukemia7New agents. Semin Hematol 43(2): 96–106 19. Estey E, Plunkett W, Gandhi V, et al. (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 9(4–5):343–350 20. Thalhammer F, Geissler K, Jager U, et al. (1996) Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: A retrospective single-center study. Ann Hematol 72(4):216–222 21. Estey E (1996) Treatment of refractory AML. Leukemia 10(6):932– 936 22. Appelbaum FR, Gundacker H, Head DR, et al. (2006) Age and acute myeloid leukemia. Blood 107(9):3481–3485 23. Kantarjian HM, Keating MJ, Walters RS, et al. (1988) The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 6(2):232–238 24. Wheatley K, Burnett AK, Goldstone AH, et al. (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. Br J Haematol 107(1):69–79 25. Kern W, Haferlach T, Schoch C, et al. (2003) Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: Data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 101(1):64–70 26. Weltermann A, Fonatsch C, Haas OA, et al. (2004) Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 18(2):293–302 27. Kern W, Haferlach T, Schnittger S, et al. (2002) Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: Implications for resistance against therapy. Leukemia 16(10):2084–2091 28. Estey E, Keating MJ, Pierce S, et al. (1995) Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia 9(6):972–976 29. Anderlini P, Luna M, Kantarjian HM, et al. (1996) Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia 10(4):600–608 30. Glasmacher A, Prentice A, Gorschluter M, et al. (2003) Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3597 patients. J Clin Oncol 21(24):4615–4626 31. Mengis C, Aebi S, Tobler A, et al. (2003) Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 21(21):3933–3939 32. van Prooijen HC, Dekker AW, Punt K (1984) The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse. Br J Haematol 57(2):291– 299 33. Herzig RH, Lazarus HM, Wolff SN, et al. (1985) High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 3(7):992–997 34. Capizzi RL, Powell BL (1987) Sequential high-dose ara-C and asparaginase versus high-dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias. Semin Oncol 14(2 Suppl 1):40–50 35. Capizzi RL, Davis R, Powell B, et al. (1988) Synergy between highdose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia7A Cancer and Leukemia Group B Study. J Clin Oncol 6(3):499–508 36. Carella AM, Carlier P, Pungolino E, et al. (1993) Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group. Leukemia 7(2):196–199 37. Karanes C, Kopecky KJ, Head DR, et al. (1999) A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. Leuk Res 23(9):787–794 38. Tavernier E, Le QH, Elhamri M, et al. (2003) Salvage therapy in refractory acute myeloid leukemia: Prediction of outcome based on analysis of prognostic factors. Leuk Res 27(3):205–214
a References 73 39. Vogler WR, McCarley DL, Stagg M, et al. (1994) A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Leukemia 8(11):1847–1853 40. Daenen S, Lowenberg B, Sonneveld P, et al. (1994) Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediatedose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). Leukemia 8(1):6–10 41. Gandhi V, Estey E, Keating MJ, et al. (1996) Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87(1):256–264 42. Kornblau SM, Gandhi V, Andreeff HM, et al. (1996) Clinical and laboratory studies of 2-chlorodeoxyadenosine +/– cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10(10):1563–1569 43. Lee EJ, George SL, Amrein PC, et al. (1998) An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: Results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B. Leukemia 12(2): 139–143 44. Robak T, Wrzesien-Kus A, Lech-Maranda E, et al. (2000) Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 39(1– 2):121–129 45. List AF, Kopecky KJ, Willman CL, et al. (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 98(12):3212–3220 46. Yin J, Wheatley K, Rees JK, et al. (2001) Comparison of “sequential” versus “standard” chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial. Br J Haematol 122:164–165 47. Advani R, Saba HI, Tallman MS, et al. (1999) Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93(3):787–795 48. Greenberg PL, Lee SJ, Advani R, et al. (2004) Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). J Clin Oncol 22(6):1078–1086 49. Dantzig AH, Shepard RL, Cao J, et al. (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56(18): 4171– 4179 50. Tsimberidou A, Cortes J, Thomas D, et al. (2003) Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 27(10):893–897 51. Apostolidou E, Cortes J, Tsimberidou A, et al. (2003) Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 27(10):887–891 52. Gale RP, Horowitz MM, Rees JK, et al. (1996) Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 10(1):13–19 53. Clift RA, Buckner CD, Appelbaum FR, et al. (1992) Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 10(11):1723–1729 54. Appelbaum FR, Clift RA, Buckner CD, et al. (1983) Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood 61(5):949–953 55. Reiffers J (2000) In: Atkinson K (ed) Clinical bone marrow and blood stem cell transplantation. Cambridge University Press, Cambridge, pp 433–445 56. Byrne JL, Dasgupta E, Pallis M, et al. (1999) Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Leukemia 13(5):786–791 57. Matthews DC, Appelbaum FR, Eary JF, et al. (1995) Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85(4):1122–1131 58. Matthews D, Appelbaum FR, Eary JF, et al. (1999) Phase I Study of (131) I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94:1237–1247 59. Choi SJ, Lee JH, Lee JH, et al. (2004) Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: A high incidence of isolated extramedullary relapse. Leukemia 18(11):1789–1797 60. Seo S, Kami M, Honda H, et al. (2000) Extramedullary relapse in the so-called “sanctuary” sites for chemotherapy after donor lymphocyte infusion. Bone Marrow Transplant 25(2):226–227 61. Porter DL (2003) Donor leukocyte infusions in acute myelogenous leukemia. Leukemia 17(6):1035–1037 62. Bosi A, Bacci S, Miniero R, et al. (1997) Second allogeneic bone marrow transplantation in acute leukemia: A multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Leukemia 11(3):420–424 63. Eapen M, Giralt SA, Horowitz MM, et al. (2004) Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 34(8):721–727 64. Barker JN, Weisdorf DJ, DeFor TE, et al. (2003) Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102(5):1915–1919 65. Rocha V, Labopin M, Sanz G, et al. (2004) Transplants of umbilicalcord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351(22):2276–2285 66. Majhail NS, Brunstein CG, Wagner JE (2006) Double umbilical cord blood transplantation. Curr Opin Immunol 18(5):571–575 67. Sierra J, Storer B, Hansen JA, et al. (1997) Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 89(11):4226–4235 68. Forman SJ, Schmidt GM, Nademanee AP, et al. (1991) Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol 9(9):1570– 1574
Page 1 and 2:
E.H. Estey · S.H. Faderl · H. M.
Page 3 and 4:
E. H. Estey Department of Leukemia
Page 5 and 6: VI Table of Contents 14 Philadelphi
Page 7 and 8: VIII Contributors S. H. Faderl Depa
Page 9 and 10: X Contributors D. Wartenberg Depart
Page 11 and 12: Therapy of AML Elihu Estey Contents
Page 13 and 14: a 1.2 · Standard Therapy 3 Table 1
Page 15 and 16: a 1.2 · Standard Therapy 5 Table 1
Page 17 and 18: a 1.2 · Standard Therapy 7 tween G
Page 19 and 20: a 1.2 · Standard Therapy 9 Fig. 1.
Page 21 and 22: a 1.2 · Standard Therapy 11 of tre
Page 23 and 24: a 1.2 · Standard Therapy 13 Table
Page 25 and 26: a 1.2 · Standard Therapy 15 permit
Page 27 and 28: a References 17 19. Care RS, Valk P
Page 29 and 30: a References 19 6-thioguanine in th
Page 31 and 32: Acute Myeloid Leukemia: Epidemiolog
Page 33 and 34: a 3.1 · Epidemiology 49 3.1.4 Gend
Page 35 and 36: a 3.2 · Etiology 51 part of the in
Page 37 and 38: a 3.2 · Etiology 53 for the develo
Page 39 and 40: a References 55 38. Crane MM, Stom
Page 41 and 42: Relapsed and Refractory Acute Myelo
Page 43 and 44: a 4.2 · Prognostic Factors in Pati
Page 45 and 46: a 4.3 · Treatment of Relapsed and
Page 47 and 48: a 4.4 · Hematopoietic Stem Cell Tr
Page 49 and 50: a 4.6 · Gemtuzumab Ozogamicin 65 T
Page 51 and 52: a 4.7 · Relapsed and Refractory Ac
Page 53 and 54: a 4.7 · Relapsed and Refractory Ac
Page 55: a References 71 The ability of immu
Page 59 and 60: a References 75 95. Sievers EL, Lar
Page 61 and 62: Part II - Acute Lymphoblastic Leuke
Page 63 and 64: 78 Chapter 5 · Acute Lymphoblastic
Page 79 and 80: Molecular Biology and Genetics Meir
Page 81 and 82: a 6.3 · Structural Aberrations 97
Page 83 and 84: a 6.3 · Structural Aberrations 99
Page 85 and 86: a 6.5 · Molecular Aberrations 101
Page 87 and 88: a References 103 clear that homozyg
Page 89 and 90: a References 105 53. Chim CS, Tam C
Page 91 and 92: a References 107 122. Lennard L, Li
Page 93 and 94: Diagnosis of Acute Lymphoblastic Le
Page 95 and 96: a 8.3 · Cytochemistry and Immunoph
Page 97 and 98: a 8.5 · Cytogenetic and Molecular
Page 99 and 100: a 8.5 · Cytogenetic and Molecular
Page 101 and 102: a References 127 including the reti
Page 103 and 104: a References 129 47. Kita K, Shirak
Page 105 and 106: Acute Lymphoblastic Leukemia: Clini
Page 107 and 108:
a 7.3 · Diagnosis 111 or neoplasti
Page 109 and 110:
a 7.3 · Diagnosis 113 Fig. 7.2. Hi
Page 111 and 112:
a 7.3 · Diagnosis 115 The vast maj
Page 113 and 114:
a References 117 dren: Biologic bas
Page 115 and 116:
General Approach to the Therapy of
Page 117 and 118:
a 9.3 · New Agents 133 dose methot
Page 119 and 120:
a References 135 4. Gökbuget N, Ho
Page 121 and 122:
138 Chapter 10 · Recent Clinical T
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
146 Chapter 11 · Conventional Ther
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
ALL Therapy: Review of the MD Ander
Page 145 and 146:
a 12.2 · The Hyper-CVAD Regimen in
Page 147 and 148:
a 12.3 · Subset-Specific Approache
Page 149 and 150:
Treatment of Adult ALL According to
Page 151 and 152:
a 13.2 · Therapy for Younger (15-6
Page 153 and 154:
a 13.3 · Therapy of Ph/BCR-ABL-Pos
Page 155 and 156:
a 13.5 · Prognostic Factors 173 13
Page 157 and 158:
a References 175 Only patients with
Page 159 and 160:
Philadelphia Chromosome-Positive Ac
Page 161 and 162:
a 14.2 · Molecular Biology of the
Page 163 and 164:
a 14.3 · Treatment of Ph+ ALL 181
Page 165 and 166:
a 14.4 · Hematopoietic Stem Cell T
Page 167 and 168:
a References 185 2. Kurzrock R, Sht
Page 169 and 170:
a References 187 56. Mori T, Manabe
Page 171 and 172:
a References 189 acute lymphoblasti
Page 173 and 174:
192 Chapter 15 · Burkitt’s Acute
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
204 Chapter 16 · Treatment of Lymp
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
216 Chapter 17 · The Role of Allog
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
230 Chapter 18 · The Role of Autol
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
238 Chapter 19 · Novel Therapies i
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
248 Chapter 20 · Minimal Residual
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
264 Chapter 21 · Central Nervous S
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
276 Chapter 22 · Relapsed Acute Ly
Page 259 and 260:
278 Chapter 22 · Relapsed Acute Ly
Page 261 and 262:
Emergencies in Acute Lymphoblastic
Page 263 and 264:
a 23.5 · Hyperleukocytosis 283 LA
Page 265 and 266:
a 23.9 · Neurological Complication
Page 267 and 268:
a References 287 29. Hingorani AD,
Page 269 and 270:
Subject Index A aberrant methylatio
Page 271 and 272:
a Subject Index 291 CREB, see enhan
Page 273 and 274:
a Subject Index 293 MUD, see matche
show all

Acute Leukemias - Republican Scientific Medical Library

Create successful ePaper yourself

Delete template?

Save as template?